News Related to Dr. Reddy's Laboratories

Related coverage linked through entity extraction aliases.

Natco Pharma Receives Approval for Generic Semaglutide in India, Launch Planned for March

Feb 13, 2026

Natco Pharma has received approval from India's CDSCO to manufacture and market generic semaglutide injection, with a March 2026 launch planned. The approval comes amid patent litigation and intense competition in India's rapidly expanding diabetes and obesity drug market.

Indian Drugmakers Race to Launch Generic Weight-Loss Drugs at 60% Discount

Feb 13, 2026

Dr Reddy's and Biocon plan to launch generic versions of Novo Nordisk's weight-loss drugs at up to 60% below branded prices as semaglutide patents expire, targeting a global market projected to reach $150 billion by the early 2030s.